High mortality among hospitalized adult patients with COVID-19 pneumonia in Peru: A single centre retrospective cohort study

PLoS One. 2022 Mar 8;17(3):e0265089. doi: 10.1371/journal.pone.0265089. eCollection 2022.

Abstract

Background: Peru is the country with the world's highest COVID-19 death rate per capita. Characteristics associated with increased mortality among adult patients with COVID-19 pneumonia in this setting are not well described.

Methods: Retrospective, single-center cohort study including 1537 adult patients hospitalized with a diagnosis of SARS-CoV-2 pneumonia between May 2020 and August 2020 at a national hospital in Lima, Peru. The primary outcome measure was in-hospital mortality.

Results: In-hospital mortality was 49.71%. The mean age was 60 ± 14.25 years, and 68.38% were males. We found an association between mortality and inflammatory markers, mainly leukocytes, D-dimer, lactate dehydrogenase, C-reactive protein and ferritin. A multivariate model adjusted for age, hypertension, diabetes mellitus, and corticosteroid use demonstrated that in-hospital mortality was associated with greater age (RR: 2.01, 95%CI: 1.59-2.52) and a higher level of oxygen requirement (RR: 2.77, 95%CI: 2.13-3.62). Conclusions: In-hospital mortality among COVID-19 patients in Peru is high and is associated with greater age and higher oxygen requirements.

MeSH terms

  • Age Factors
  • Aged
  • C-Reactive Protein / analysis
  • COVID-19 / diagnosis
  • COVID-19 / epidemiology
  • COVID-19 / mortality*
  • COVID-19 / virology
  • Comorbidity
  • Female
  • Ferritins / analysis
  • Fibrin Fibrinogen Degradation Products / analysis
  • Hospital Mortality
  • Hospitalization / statistics & numerical data*
  • Humans
  • Male
  • Middle Aged
  • Peru / epidemiology
  • Respiration, Artificial
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2 / isolation & purification

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D
  • C-Reactive Protein
  • Ferritins

Grants and funding

The author(s) received no specific funding for this work.